Vivaldi Biosciences
Bronze Sponsor
Vivaldi is developing intranasal vaccines for superior protection against respiratory diseases. Our lead vaccines are: DeltaFLU universal influenza vaccine, for protection against all influenza A and B strains, with clinical development supported by the NIAID and EU; and DelNS1 H5N1, a Phase 2-ready vaccine for protection against HPAI influenza H5N1 strains. Our vaccines generate a broadly protective mucosal and systemic immune response targeting the full range of influenza virus antigens. Rapid mucosal protection provides the potential to block virus transmission and disease spread. We will present at WVC results from recent studies in the ferret model indicating the potential of DeltaFLU to prevent transmission of influenza A and B type viruses. Our vaccines are composed of genetically attenuated, replication-deficient influenza vaccine strains from which the NS1 gene is deleted. Deletion of NS1 results in the ability to rapidly induce interferon, conferring a self-adjuvant effect and activating multiple immune mechanisms, including broadly cross-neutralizing local and systemic antibodies and T cells. Deletion of NS1 also makes the vaccines safe, with no viral progeny and no detectable shedding of vaccine virus from recipients. Four completed clinical studies demonstrated safety, immunogenicity, and the replication-deficient phenotype. Our Vero cell-based GMP manufacturing system produces the vaccines at high yields and high purity.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events